A leading medical technology company focusing on continuous glucose monitoring (CGM) technology, DexCom, has launched the first ever over-the-counter (OTC) glucose biosensor in the US market.
Known as Stelo, the wearable allows users to monitor glucose levels in real-time via a smartphone app, eliminating the need for a traditional invasive fingerstick.
By displaying the glucose readings directly on the smartphone, users can understand how sleep, food, and exercise affect their glucose levels. With this valuable insight, the device empowers users to make well-informed lifestyle choices beneficial to their well-being.
DexCom’s new glucose biosensor provides millions of Americans suffering from type 2 diabetes with an option to manage their glucose painlessly from the comfort of their smartphones without having to get a prescription to acquire the device.
The device is designed for adults battling type 2 diabetes who are not under insulin doses. It can also help adults with prediabetes who are seeking to optimize their health and keep their glucose levels in check.
Why Stelo is a Game-changer
Unlike the traditional blood glucose meter, Stelo is the only OTC biosensor that does not require finger pricking. Additionally, the device has a personalized app that provides users weekly, daily, and sessional summaries to help them develop healthy habits.
The biosensor is also the only OTC device offering spike detection, enabling users to identify substantial glucose fluctuations. It also has the highest waterproof rating among its peers and a relatively longer wear time of up to 15 days.
Stelo is currently available for purchase on Stelo.com. It’s compatible with Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) and offers flexible payment options. Customers can opt for a pay-as-you-go or monthly subscription.
